RxDoctor Payments Data

Cynthia Bascara

Adult Health · East Windsor, NJNPI 1790038545

Payments from drug & device makers

$3,686in general payments, 2019–2025

Across 90 payments — averaging $40.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$828
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$366
  • Phathom Pharmaceuticals, Inc.$363
  • Novo Nordisk$338
  • Medline Industries LP$149
  • plus $533 from 10 others

What the payments were for

  • Food & beverage$3,686100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,686 in reported general payments places this provider in the 90th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$55,381
Medicare patients
381
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide31$31,936
FarxigaDapagliflozin Propanediol12$15,343
EliquisApixaban11$9,074
Rosuvastatin Calcium42$599
Famotidine30$561
Albuterol Sulfate HfaAlbuterol Sulfate21$480
Atorvastatin Calcium36$457
Levocetirizine Dihydrochloride29$416
Levothyroxine Sodium27$414
FenofibrateFenofibrate Nanocrystallized20$300
Metoprolol Succinate22$292
Losartan Potassium30$284
Ibuprofen21$272
Omeprazole21$243
Gabapentin14$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$126$31,93631 claims
AstraZenecaFarxiga$1,108$15,34312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,135 adult health providers in New Jersey.

Other adult health in East Windsor

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →